Genetic markers of enhanced functional antibody responses to COVID-19 vaccination

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction

Substantial population-level variation in vaccine-specific antibody responses has been observed following global coronavirus disease 2019 (COVID-19) vaccination efforts. Beyond the influence of clinical and demographic features, immunogenetic variation is suggested to underlie divergent serological responses following COVID-19 vaccination of distinct populations.

Methods

Immunoglobulin G1 (IgG1) allotypic markers (G1m) for 121 COVID-19 vaccinated healthy adults were genotyped via Sanger sequencing. Vaccine-specific IgG and Fc gamma receptor (FcγR) engagement were characterised via bead-based multiplex array.

Results

Following two COVID-19 vaccine doses, G1m1,17 +/+ compared to G1m-1,3 +/+ vaccinees had increased IgG and FcγR engagement specific for the antigenically conserved SARS-CoV-2 Spike 2 (S2) domain. IgG targeting antigenically novel SARS-CoV-2 receptor binding domain (RBD) trended higher in G1m1,17 +/+ vaccinees, facilitating increased RBD-specific FcγR2a-R131 and FcγR2b binding.

Conclusion

Primary COVID-19 vaccination induced increased S2-specific IgG in G1m1,17 +/+ vaccinees, potentially facilitating enhanced anti-viral FcγR activation. Validation in larger cohorts may inform optimisation of next-generation vaccination strategies.

Article activity feed